

Sai Life Sciences to double process R&D capacity with new facility in Hyderabad

27 October 2025 | News

Addressing the need for scalable capacity across CMC development and manufacturing



Sai Life Sciences, one of India's fastest growing Contract Research, Development, and Manufacturing Organizations (CRDMO), has announced the groundbreaking for a new CMC Process R&D Center at its integrated R&D campus in Hyderabad.

Scheduled for completion by September 2026, the facility will double the company's Process R&D capacity, while adding new capabilities in peptide development, oligo intermediates & linkers development, formulation development and early phase clinical supplies.

The new CMC Process R&D Center represents a strategic investment in scale, sustainability, and specialisation. Designed to support both Full-Time Equivalent (FTE) and Dedicated Project Capacity (DPC) engagement models, it will enable flexible collaboration with global innovators—from early development to late-stage CMC programmes. This model further strengthens Sai Life Sciences' position as a preferred partner for integrated drug development, aligned with the growing demand for end-to-end, partnership-driven solutions that deliver on both quality and timelines.

Highlights of the upcoming Process R&D Block include- Total built-up area of 100,000 sq. ft. (9300 sq.m.) over five floors; 140 process chemistry fume hoods with an integrated satellite analytical lab; Dedicated laboratories for peptides and oligo intermediates & linkers; 25,000 sq. ft. centralised analytical laboratory; NCE formulation development and early-phase clinical supply capabilities; Kilo lab for early clinical manufacturing; Containment down to OEL 4 (1 µg/m³); Designed as a 'Green

Building'.